Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 16/20 | 0.51 |
| ▸ | CTSL | P07711 | 8/20 | 0.41 |
| ▸ | CTSS | P25774 | 7/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.35 |
| ▸ | CTSB | P07858 | 2/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4046026 | 0.94 | CTSK (0.51) | CTSKCTSLCTSSALDH1A1CTSB | |
| SCHEMBL4045577 | 0.88 | CTSK (0.41) | CTSKCTSLCTSSALDH1A1CTSB | |
| SCHEMBL4050120 | 0.87 | CTSK (0.51) | CTSKCTSLCTSSALDH1A1CTSB | |
| SCHEMBL4046025 | 0.87 | CTSK (0.49) | CTSKCTSLCTSSALDH1A1CTSB | |
| SCHEMBL4049326 | 0.86 | CTSK (0.42) | CTSKCTSLCTSSALDH1A1 | |
| SCHEMBL4042338 | 0.85 | CTSK (0.43) | CTSKCTSLCTSSALDH1A1CTSB | |
| SCHEMBL4048981 | 0.85 | CTSK (0.43) | CTSKCTSLCTSSALDH1A1CTSB | |
| SCHEMBL4042251 | 0.85 | CTSK (0.50) | CTSKCTSLCTSSALDH1A1CTSB | |
| SCHEMBL4046471 | 0.85 | CTSK (0.47) | CTSKCTSLCTSSALDH1A1CTSB | |
| SCHEMBL4045333 | 0.85 | CTSK (0.53) | CTSKCTSLCTSSALDH1A1CTSB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1436291-B1 | INDOLIZINES AS KINASE PROTEIN INHIBITORS | AVENTIS PHARMA SA (FR) | 2009-01-14 | — | — | EP | disclosed |
| US-20070238734-A1 | JNK INHIBITORS | SANOLI-AVENTIS (FR) | 2007-10-11 | — | — | US | disclosed |
| US-7148215-B2 | Prodrugs as antihistamines or anticarcinogenic agents | AVENTIS PHARMA S.A. (FR) | 2006-12-12 | — | — | US | disclosed |
| US-20050009831-A1 | Pyrrolo[1,2-a]pyrazine-8-carboxamides are JNK inhibitors, useful as anticarcinogenic agents | AVENTIS PHARMA S.A, (FR) | 2005-01-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070238734-A1 | JNK INHIBITORS | MAP3K7, MAPKAPK2, MAPK7 | CTSK 1880/4885CTSL 3762/4885CTSS 3389/4885 |
| US-20050009831-A1 | Pyrrolo[1,2-a]pyrazine-8-carboxamides are JNK inhibitors, useful as anticarcinogenic agents | CNKSR1, ROS1, NRAS | CTSK 2460/4885CTSL 2973/4885CTSS 2896/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.